191 related articles for article (PubMed ID: 36749302)
1. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
[No Abstract] [Full Text] [Related]
2. Corticosteroids for the treatment of Duchenne muscular dystrophy.
Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
[TBL] [Abstract][Full Text] [Related]
3. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
[TBL] [Abstract][Full Text] [Related]
4. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.
Shieh PB; Elfring G; Trifillis P; Santos C; Peltz SW; Parsons JA; Apkon S; Darras BT; Campbell C; McDonald CM; ; ; ;
J Comp Eff Res; 2021 Dec; 10(18):1337-1347. PubMed ID: 34693725
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
7. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
[TBL] [Abstract][Full Text] [Related]
9. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
[TBL] [Abstract][Full Text] [Related]
11. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
[TBL] [Abstract][Full Text] [Related]
12. Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1.
McDonald CM; Mayer OH; Hor KN; Miller D; Goemans N; Henricson EK; Marden JR; Freimark J; Lane H; Zhang A; Frean M; Trifillis P; Koladicz K; Signorovitch J;
J Neuromuscul Dis; 2023; 10(1):67-79. PubMed ID: 36565131
[TBL] [Abstract][Full Text] [Related]
13. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD; Skalsky A; McDonald CM
J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
[No Abstract] [Full Text] [Related]
15. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study.
Wong BL; Cook T; Miller H
J Comp Eff Res; 2022 Aug; 11(11):779-786. PubMed ID: 35713895
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C;
J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228
[TBL] [Abstract][Full Text] [Related]
17. Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial.
Reddy C; Patil AN; Suthar R; Sankhyan N; Sirari T; Kumar A; Bhattacharjee S; Saxena S; Saini AG; Sahu JK
Eur J Paediatr Neurol; 2022 May; 38():77-84. PubMed ID: 35500465
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Balaban B; Matthews DJ; Clayton GH; Carry T
Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H;
Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484
[TBL] [Abstract][Full Text] [Related]
20. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
